In a nutshell The authors aimed to determine the effectiveness of enzalutamide (Xtandi ) in metastatic (cancer that has spread) hormone-resistant prostate cancer compared to the standard bicalutamide (Casodex) treatment. Some background Hormone deprivation therapy is a common treatment used in prostate cancer. It targets the...
Read MoreConfined or spread disease-Spread beyond the prostate gland Posts on Medivizor
Metabolic syndrome increases disease progression in advanced prostate cancer
In a nutshell This study investigated the impact of metabolic syndrome on treatment outcome with abiraterone acetate (Zytiga) for hormone-resistant prostate cancer. Researchers concluded that metabolic syndrome has an adverse outcome on disease progression in advanced prostate cancer. Some background Hormone therapy is a common treatment used in...
Read MoreRadiation therapy slows disease progression in advanced prostate cancer
In a nutshell This study investigated the effects of radiation therapy in slowing disease progression in metastatic prostate cancer. Researchers concluded that radiation to the primary tumor site improves overall survival and slows the progression of metastatic prostate cancer. Some background Radiation therapy involves directing...
Read MorePersonalized peptide vaccine shows promising early-phase results
In a nutshell This study examined personalized peptide vaccine (PPV) immunotherapy in the treatment of advanced metastatic prostate cancer. Researchers reported that patients treated with PPV showed delayed disease progression and increased overall survival. Some background Immunotherapy has recently been under intense investigation as a possible...
Read MoreHow important is drug sequence in advanced prostate cancer survival?
In a nutshell The authors aimed to determine the benefit of sequencing docetaxel (Taxotere) and abiraterone (Zytiga) treatment to improve progression-free survival (patients who did not experience cancer growth after treatment) in patients with metastaic (cancer that has spread) hormone-resistant (cancer that does not respond to hormone...
Read MoreCan toremifene improve the effectiveness of androgen-deprivation therapy?
In a nutshell The authors aimed to determine the effect of toremifene (Fareston) and raloxifene (Evista) when added to hormone therapy in prostate cancer patients who had not received previous treatments. The authors concluded that toremifene and hormone therapy significantly improved the rate of biochemical recurrence (BCR, a rise in prostate...
Read MorePain relief for bone metastasis in prostate cancer
In a nutshell This study compared the effectiveness of ibandronate (Boniva) with the more conventional radiotherapy in reducing metastatic bone pain in prostate cancer. Some background Bone metastasis (cancer spread to the bone) is a common and painful occurrence in prostate cancer. There are a range of treatments available, with radiotherapy...
Read MoreReview of advanced prostate cancer treatments
In a nutshell The authors analyzed treatment options available for advanced prostate cancer. Some background At the first St. Gallen Advanced Prostate Cancer Conference leading experts met to determine the most up-to-date guidelines for the treatment of advanced prostate cancer. Advanced prostate cancer is cancer that has spread...
Read MoreThe Promise of Immunotherapy in Treating Advanced Prostate Cancer (VIDEO)
Published By : Patient Power Date : Aug 05, 2015 Original Title : The Promise of Immunotherapy in Treating Advanced Prostate Cancer ...
Read MoreLooking for patients with metastatic hormone-resistant prostate cancer to evaluate the benefit of using immunotherapy and radiation
In a nutshell This phase II trial based in Dallas, Texas aims to determine the effect of immunotherapy and stereotactic ablative body radiation as a metastatic hormone-resistant prostate cancer treatment. The main outcome to be investigated is time from treatment until cancer progression. The details Metastatic prostate cancer is cancer that...
Read MoreBone biomarkers predicting prostate cancer survival
In a nutshell The authors determined the value of bone biomarkers in predicting poor survival in patients with hormone resistant prostate cancer. Some background Hormone therapy is a common treatment for prostate cancer. It targets the male sex hormones active in prostate cancer, such as testosterone. Some patients can develop...
Read MoreEnzalutamide in hormone-resistant prostate cancer – a review
In a nutshell The authors reviewed the benefit of enzalutamide (Xtandi) in treating advanced hormone-resistant (castration-resistant) prostate cancer. Some background Hormone therapy is a common treatment used in prostate cancer. It targets the male sex hormones active in prostate cancer, such as testosterone. Some patients...
Read More
